Loading...
XTAE
BONS
Market cap117mUSD
Jul 10, Last price  
29.50ILS
Name

Bonus Biogroup Ltd

Chart & Performance

D1W1MN
XTAE:BONS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-8.30%
Rev. gr., 5y
%
Revenues
0k
Net income
-24m
L-11.99%
-17,973,000-9,701,000-11,207,000-13,459,000-16,046,000-20,197,000-18,735,000-22,240,000-22,021,000-90,076,000-38,703,000-28,529,000-27,826,000-24,490,000
CFO
-15m
L-30.13%
-9,672,000-7,631,000-7,907,000-8,069,000-9,625,000-11,823,000-13,427,000-13,113,000-15,746,000-39,839,000-28,815,000-26,397,000-21,374,000-14,933,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is headquartered in Haifa, Israel.
URL
http://www.bonusbiogroup.com
IPO date
Aug 20, 1993
Employees
57
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT